RxDoctor Payments Data

Martin Edep, MD

Cardiovascular Disease · Boca Raton, FLNPI 1245222355

Payments from drug & device makers

$3,481in general payments, 2019–2025

Across 150 payments — averaging $23.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$916
  • Philips North America LLC$694
  • Amgen$392
  • Novartis$286
  • Pfizer$209
  • E.r. Squibb & Sons, L.L.C.$148
  • plus $835 from 17 others

What the payments were for

  • Food & beverage$3,481100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,481 in reported general payments places this provider in the 50th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$745,893
Medicare patients
899
Services billed
14,527

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban231$233,900
XareltoRivaroxaban123$123,445
Repatha SureclickEvolocumab93$74,490
EntrestoSacubitril/Valsartan21$36,332
MultaqDronedarone Hcl25$33,082
OzempicSemaglutide19$26,545
Praluent PenAlirocumab27$16,930
MounjaroTirzepatide14$14,480
VascepaIcosapent Ethyl25$13,975
JardianceEmpagliflozin12$10,909
Nebivolol Hcl88$7,416
Rosuvastatin Calcium409$5,717
Midodrine Hcl46$4,745
Candesartan Cilexetil42$4,348
SynthroidLevothyroxine Sodium32$3,757

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$209$233,900231 claims
Johnson & JohnsonXarelto$121$123,445123 claims
NovartisEntresto$286$36,33221 claims
Sanofi-aventis U.S. LLCMultaq$33$33,08225 claims
Boehringer IngelheimJardiance$23$10,90912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →